237 related articles for article (PubMed ID: 34885007)
1. Chromosome Imbalances in Neuroblastoma-Recent Molecular Insight into Chromosome 1p-deletion, 2p-gain, and 11q-deletion Identifies New Friends and Foes for the Future.
Guan J; Hallberg B; Palmer RH
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885007
[TBL] [Abstract][Full Text] [Related]
2. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification.
Plantaz D; Vandesompele J; Van Roy N; Lastowska M; Bown N; Combaret V; Favrot MC; Delattre O; Michon J; Bénard J; Hartmann O; Nicholson JC; Ross FM; Brinkschmidt C; Laureys G; Caron H; Matthay KK; Feuerstein BG; Speleman F
Int J Cancer; 2001 Mar; 91(5):680-6. PubMed ID: 11267980
[TBL] [Abstract][Full Text] [Related]
3. Evolution of unbalanced gain of distal chromosome 2p in neuroblastoma.
Stallings RL; Carty P; McArdle L; Mullarkey M; McDermott M; O'Meara A; Ryan E; Catchpoole D; Breatnach F
Cytogenet Genome Res; 2004; 106(1):49-54. PubMed ID: 15218241
[TBL] [Abstract][Full Text] [Related]
4. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
5. Low DLG2 gene expression, a link between 11q-deleted and MYCN-amplified neuroblastoma, causes forced cell cycle progression, and predicts poor patient survival.
Keane S; Améen S; Lindlöf A; Ejeskär K
Cell Commun Signal; 2020 Apr; 18(1):65. PubMed ID: 32312269
[TBL] [Abstract][Full Text] [Related]
6. Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q.
Boensch M; Oberthuer A; Fischer M; Skowron M; Oestreich J; Berthold F; Spitz R
Diagn Mol Pathol; 2005 Sep; 14(3):177-82. PubMed ID: 16106200
[TBL] [Abstract][Full Text] [Related]
7. Coordinate deletion of chromosome 3p and 11q in neuroblastoma detected by comparative genomic hybridization.
Breen CJ; O'Meara A; McDermott M; Mullarkey M; Stallings RL
Cancer Genet Cytogenet; 2000 Jul; 120(1):44-9. PubMed ID: 10913676
[TBL] [Abstract][Full Text] [Related]
8. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Clin Cancer Res; 2003 Jan; 9(1):52-8. PubMed ID: 12538451
[TBL] [Abstract][Full Text] [Related]
9. Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements.
Javanmardi N; Fransson S; Djos A; Umapathy G; Östensson M; Milosevic J; Borenäs M; Hallberg B; Kogner P; Martinsson T; Palmer RH
Genes Chromosomes Cancer; 2020 Jan; 59(1):50-57. PubMed ID: 31340081
[TBL] [Abstract][Full Text] [Related]
10. Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Clin Cancer Res; 2003 Oct; 9(13):4835-40. PubMed ID: 14581355
[TBL] [Abstract][Full Text] [Related]
11. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma.
Spitz R; Hero B; Simon T; Berthold F
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3368-73. PubMed ID: 16740759
[TBL] [Abstract][Full Text] [Related]
12. 11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma.
Siaw JT; Javanmardi N; Van den Eynden J; Lind DE; Fransson S; Martinez-Monleon A; Djos A; Sjöberg RM; Östensson M; Carén H; Trøen G; Beiske K; Berbegall AP; Noguera R; Lai WY; Kogner P; Palmer RH; Hallberg B; Martinsson T
Cell Rep; 2020 Sep; 32(12):108171. PubMed ID: 32966799
[TBL] [Abstract][Full Text] [Related]
13. ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.
Borenäs M; Umapathy G; Lai WY; Lind DE; Witek B; Guan J; Mendoza-Garcia P; Masudi T; Claeys A; Chuang TP; El Wakil A; Arefin B; Fransson S; Koster J; Johansson M; Gaarder J; Van den Eynden J; Hallberg B; Palmer RH
EMBO J; 2021 Feb; 40(3):e105784. PubMed ID: 33411331
[TBL] [Abstract][Full Text] [Related]
14. Molecular targeting therapies for neuroblastoma: Progress and challenges.
Zafar A; Wang W; Liu G; Wang X; Xian W; McKeon F; Foster J; Zhou J; Zhang R
Med Res Rev; 2021 Mar; 41(2):961-1021. PubMed ID: 33155698
[TBL] [Abstract][Full Text] [Related]
15. 11q deletion in neuroblastoma: a review of biological and clinical implications.
Mlakar V; Jurkovic Mlakar S; Lopez G; Maris JM; Ansari M; Gumy-Pause F
Mol Cancer; 2017 Jun; 16(1):114. PubMed ID: 28662712
[TBL] [Abstract][Full Text] [Related]
16. Estimation of copy number aberrations: Comparison of exome sequencing data with SNP microarrays identifies homozygous deletions of 19q13.2 and CIC in neuroblastoma.
Fransson S; Östensson M; Djos A; Javanmardi N; Kogner P; Martinsson T
Int J Oncol; 2016 Mar; 48(3):1103-16. PubMed ID: 26794043
[TBL] [Abstract][Full Text] [Related]
17. Are gains of chromosomal regions 7q and 11p important abnormalities in neuroblastoma?
Stallings RL; Howard J; Dunlop A; Mullarkey M; McDermott M; Breatnach F; O'Meara A
Cancer Genet Cytogenet; 2003 Jan; 140(2):133-7. PubMed ID: 12645651
[TBL] [Abstract][Full Text] [Related]
18. Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.
Berbegall AP; Villamón E; Piqueras M; Tadeo I; Djos A; Ambros PF; Martinsson T; Ambros IM; Cañete A; Castel V; Navarro S; Noguera R
Oncogene; 2016 Mar; 35(11):1423-32. PubMed ID: 26119945
[TBL] [Abstract][Full Text] [Related]
19. Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q.
Fischer M; Bauer T; Oberthür A; Hero B; Theissen J; Ehrich M; Spitz R; Eils R; Westermann F; Brors B; König R; Berthold F
Oncogene; 2010 Feb; 29(6):865-75. PubMed ID: 19901960
[TBL] [Abstract][Full Text] [Related]
20. Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.
Cetinkaya C; Martinsson T; Sandgren J; Träger C; Kogner P; Dumanski J; Díaz de Ståhl T; Hedborg F
BMC Cancer; 2013 May; 13():231. PubMed ID: 23656755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
